Showing results (51-60 of 85) with videos related to

Sort By:
Pageof 9
Molecular Neurodegeneration|April 27, 2021
Mitochondrial complex I abnormalities is associated with tau and clinical symptoms in mild Alzheimer's diseaseTatsuhiro Terada, Joseph Therriault, Min Su Peter Kang, et al.
The Journal of Clinical Investigation|June 27, 2017
IFN-γ-related mRNA profile predicts clinical response to PD-1 blockadeMark Ayers, Jared Lunceford, Michael Nebozhyn, et al.
Molecular Genetics & Genomic Medicine|March 25, 2015
A slowly progressive form of limb-girdle muscular dystrophy type 2C associated with founder mutation in the SGCG gene in Puerto Rican HispanicsSamiah A Al-Zaidy, Vinod Malik, Kelley Kneile, et al.
Genetics in Medicine : Official Journal of the American College of Medical Genetics|June 23, 2017
Systematic design and comparison of expanded carrier screening panelsKyle A Beauchamp, Dale Muzzey, Kenny K Wong, et al.
Alzheimer'S & Dementia : the Journal of the Alzheimer'S Association|December 23, 2025
Alzheimer's Imaging ConsortiumJulie Ottoy, Min Su Peter Kang, Eric Yin, et al.
Neurology|February 20, 2026
Neuroimaging Biomarkers of Disease Progression and Cognitive Change in Patients With Retinal Vasculopathy With Cerebral LeukoencephalopathyAndria L Ford, Peter Kang, Slim Fellah, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|January 22, 2015
Phase I dose-escalation trial of checkpoint kinase 1 inhibitor MK-8776 as monotherapy and in combination with gemcitabine in patients with advanced solid tumorsAdil I Daud, Michelle T Ashworth, Jonathan Strosberg, et al.
European Journal of Cancer (Oxford, England : 1990)|September 7, 2016
Health-related quality of life in the randomised KEYNOTE-002 study of pembrolizumab versus chemotherapy in patients with ipilimumab-refractory melanomaDirk Schadendorf, Reinhard Dummer, Axel Hauschild, et al.
JAMA Oncology|December 21, 2018
Efficacy and Safety of Pembrolizumab for Heavily Pretreated Patients With Advanced, Metastatic Adenocarcinoma or Squamous Cell Carcinoma of the Esophagus: The Phase 2 KEYNOTE-180 StudyManish A Shah, Takashi Kojima, Daniel Hochhauser, et al.
Lancet (London, England)|June 9, 2018
Pembrolizumab versus paclitaxel for previously treated, advanced gastric or gastro-oesophageal junction cancer (KEYNOTE-061): a randomised, open-label, controlled, phase 3 trialKohei Shitara, Mustafa Özgüroğlu, Yung-Jue Bang, et al.
Pageof 9